Lead sponsor
Beijing QL Biopharmaceutical Co.,Ltd
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
1
Active
278
Total enrollment
11
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Active, not recruiting
1
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Efficacy and Safety of ZT006 in Overweight and Obese ParticipantsBMI ≥28Ph 2Active, not recruiting184
Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese ParticipantsBMI 19-35Ph 1Completed94